Roche announced the expansion of its collaboration with the U.S. Centers for Disease Control and Prevention (CDC) to strengthen laboratory capabilities in countries greatly affected by the HIV and tuberculosis (TB) epidemics. Through the implementation of a public-private partnership (PPP), named "Lab Networks for Health," Roche and the CDC will seek to improve HIV and tuberculosis prevention, detection, and treatment outcomes in select countries of Africa, Eastern Europe, Central Asia, and the Western Hemisphere (e.g., Latin America, Central America, and Caribbean Regions). Specifically, Roche and CDC intend to increase laboratory human resource capacity building through expanded training interventions and to support laboratory quality management systems and improvement programs. The partners will also seek to optimise laboratory workflows and integrated diagnostics networks to increase access to multi-pathogen testing capabilities to enhance pandemic preparedness.

In addition, they will work to improve local and regional capacity for effective laboratory waste management and related biosafety approaches. A recent UNAIDS report highlighted the faltering progress for HIV programs, with approximately 1.5 million new infections occurring in 2021; more than 1 million over the global target. Reversing years of declines, about 10.6 million people worldwide became ill with tuberculosis in 2021, and only 6.4 million of them were diagnosed, according to global reporting.